Brainsway

Brainsway Ltd. is a commercial stage medical device company, which focuses on the development and sale of non-invasive neuromodulation products using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The Deep TMS uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. The company was founded by Avner Hagai, Yiftach Roth, Abraham Zangen, and David Zacut on November 7, 2006 and is headquartered in Jerusalem, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Brainsway Ltd. engages in the development and sale of non-invasive neurostimulation treatments using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The Deep TMS uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. The company was founded by Avner Hagai, Yiftach Roth, Abraham Zangen, and David Zacut on November 7, 2006 and is headquartered in Jerusalem, Israel.

The Company's Groundbreaking Deep TMS™ Treatment is Included in Israel's Health Basket of Essential Medical Services The Company's Groundbreaking Deep TMS™ Treatment is Included in Israel's Health Basket of Essential Medical Services

BrainsWay Announces Insurance Coverage by Israeli Ministry of Health for the Treatment of Depression

BURLINGTON, Mass. and JERUSALEM, June 22, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that Christopher von Jako, PhD, BrainsWay's President, and Chief Executive Officer, will participate in a fireside chat and panel discussion at the H.C. Wainwright 1st Annual Mental Health Conference being held at the Lotte New York Palace Hotel on June 27, 2022.

BrainsWay to Present at the H.C. Wainwright 1st Annual Mental Health Conference

BrainsWay Ltd. (NASDAQ:BWAY ) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Bob Yedid – LifeSci Advisors Chris von Jako – President and Chief Executive Officer Scott Areglado – Chief Financial Officer Conference Call Participants Jeffery Cohen – Ladenburg Thalmann Jayson Bedford – Raymond James Steven Lichtman – Oppenheimer Jason Wittes – Loop Capital Carl Byrnes – Northland Capital Markets Operator Greetings, and welcome to BrainsWay First Quarter 2022 Earnings Conference Call.

BrainsWay's (BWAY) CEO Chris von Jako on Q1 2022 Results - Earnings Call Transcript

Revenue Growth of 30% Year-over-Year in Q1 2022

BrainsWay Reports First Quarter 2022 Financial Results and Operational Highlights

BrainsWay will donate $5 per share, $2 per comment, and $1 per like to support the work of Mental Health America BrainsWay will donate $5 per share, $2 per comment, and $1 per like to support the work of Mental Health America

BrainsWay Launches #DontMissAnotherMoment Social Media Campaign to Promote Mental Health Awareness Month

BURLINGTON, Mass. and JERUSALEM, April 27, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its first quarter financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 11, 2022. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

BrainsWay to Report First Quarter Financial Results on May 11, 2022

Dr. Seidel has more than 20 years of experience in the medical device industry Dr. Seidel has more than 20 years of experience in the medical device industry

BrainsWay Appoints Dr. Joachim Seidel as Vice President of Corporate Development and Strategy

BrainsWay's (BWAY) CEO Christopher von Jako on Q4 2021 Results - Earnings Call Transcript

Revenue Growth of 34% in 2021, with Record Quarterly and Annual Revenues

BrainsWay Reports Fourth Quarter and Full-Year 2021 Financial Results and Operational Highlights

BURLINGTON, Mass. and JERUSALEM, March 01, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will present and participate in one-on-one investor meetings at the 32nd Annual Oppenheimer Healthcare Conference.

BrainsWay to Present at the 32nd Annual Oppenheimer Healthcare Conference

BURLINGTON, Mass. and JERUSALEM, Feb. 01, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will present and participate in one-on-one investor meetings at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.

BrainsWay to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Palmetto GBA Covers Medicare Patients in Seven States Palmetto GBA Covers Medicare Patients in Seven States

BrainsWay Announces Final Local Coverage Determination Issued by Regional Medicare Administrative Contractor Palmetto GBA Providing Coverage of Deep TMS™ for the Treatment of OCD

World-Renowned Specialist in Addiction and Anxiety Treatment Joins Premier Group of Researchers and Clinicians Advising Company World-Renowned Specialist in Addiction and Anxiety Treatment Joins Premier Group of Researchers and Clinicians Advising Company

BrainsWay Announces Addition of Markus Heilig, M.D., Ph.D., to Scientific Advisory Board

BrainsWay has clearance for an expanding number of indications, which is supportive of continued growth. There is also growing evidence of the cost-effectiveness of TMS, which should lead to wider insurance coverage.

BrainsWay's Competitive Advantage Is Growing

Positive Data Support the Durability and Cost-Effectiveness of Deep TMS as a Treatment for Obsessive-Compulsive Disorder Positive Data Support the Durability and Cost-Effectiveness of Deep TMS as a Treatment for Obsessive-Compulsive Disorder

BrainsWay Announces Multiple Publications of New Real-World OCD Data for its Deep TMS™ System

The stock price of Brainsway (NASDAQ: BWAY) increased by 4.71% today. This is why it happened.

Brainsway Stock (BWAY): Why The Price Increased Today

Randomized, Placebo-Controlled, Double-Blind Pilot Study Evaluated Deep TMS Treatment in Reducing Alcohol Consumption and Craving for Adults with Alcohol Use Disorder

BrainsWay Announces Publication of Deep TMS™ Trial Results for Reduction of Heavy Drinking in Alcohol-Dependent Subjects

BrainsWay Ltd. (BWAY) CEO Christopher von Jako on Q3 2021 Results - Earnings Call Transcript

Revenue Growth of 34% Year-over-Year in Q3 2021

BrainsWay Reports Third Quarter 2021 Financial Results and Operational Highlights

BURLINGTON, Mass. and JERUSALEM, Nov. 03, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its third quarter 2021 financial results as well as operational highlights before the open of the U.S. financial markets on Wednesday, November 17, 2021. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

BrainsWay to Report Third Quarter 2021 Financial Results on November 17, 2021

Evidence Supports Use of Deep TMS as a Safe and Effective Treatment for Smoking Addiction

BrainsWay Announces Data Published in World Psychiatry on Deep Transcranial Magnetic Stimulation (Deep TMS™) for Smoking Addiction

BURLINGTON, Mass. and JERUSALEM, Sept. 09, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will present and participate in one-on-one investor meetings at two investment conferences during the month of September, as follows:

BrainsWay to Participate in Two Upcoming Investor Conferences

BURLINGTON, Mass. and JERUSALEM, Aug. 30, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will present and participate in one-on-one investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021.

BrainsWay to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

The FDA has cleared BrainsWay Ltd's (NASDAQ:BWAY) Deep Transcranial Magnetic Stimulation (Deep TMS) System to reduce comorbid anxiety symptoms in adult patients with depression, also known as anxious depression. BrainsWay submitted data from 573 patients in support of its application to the FDA.

BrainsWay Stock Gains On FDA Expanded Use Approval For Its Stimulation Device

Expanded Depression Indication Further Demonstrates Company's Leadership Position Expanded Depression Indication Further Demonstrates Company's Leadership Position

News for Brainsway Stock (BWAY)